B+
Bull case
25%
Probability
Target price
$205.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
PODD
InsuletANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
Primary-source earnings evidence was strong: revenue growth exceeded guidance, operating margin expanded, free cash flow rose to $89.5 million, and FY2026 revenue guidance was raised. The operating story is still centered on Omnipod adoption, especially international, with additional pipeline optionality from type 2 AID.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +13.4.
What can break
Direct diabetes-technology competition from Tandem and Medtronic can pressure new-user acquisition, retention, pricing, and the perceived differentiation of tubeless AID over time.
Momentum
10
Value
57
Sentiment
92
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $172.00 · Bull $205.00 · Bear $130.00Analysis 2026-05-09; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $169.86
Why
Momentum10 · Δ7d +1.5
Value57 · Δ7d -0.0
Sentiment92 · Δ7d +13.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +13.4.
Contradictions & invalidation
- • Direct diabetes-technology competition from Tandem and Medtronic can pressure new-user acquisition, retention, pricing, and the perceived differentiation of tubeless AID over time.
- • Estimated warranty costs tied to the March 2026 voluntary medical device correction reduced Q1 reported profitability by $11.7 million.
- • The setup still looks like a monitoring story rather than a clean rerating.
Catalyst clock
2026-05-06
Q1 beat-and-raise confirmed in earnings release
Lead driver: Sentiment · See AI snapshot
Momentum
10
9% active weight
Current posture
7d trendImproving
Δ7d
+1.5
Δ21d
+2.0
Value
57
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.8
Sentiment
92
62% active weight
Current posture
7d trendImproving
Δ7d
+13.4
Δ21d
+7.8
Why this grade
Composite grade A. Momentum 9.8 / Value 57.4 / Sentiment 92.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-09. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$172.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$130.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$9.69B
Beta
1.41
Shares Out
69.35M
P/E (TTM)
82.3
P/S (TTM)
7.91
P/FCF (TTM)
48.92
Rev YoY
+23.5%
EPS YoY
+234.8%
Gross Margin
+72.2%
Op Margin
+16.9%
Net Debt
$285.8M
Current Ratio
2.45
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data